Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

VERA PEER ANALYSIS

Vera Therapeutics Inc — metric-by-metric comparison with peers and the industry median

VERAVera Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityFinancial Health
VERAIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
VERA+67.2%TLX-28.2%MSB+27.6%CSL-47.6%
Year-to-Date (YTD)
VERA-20.8%TLX+55.2%MSB-23.5%CSL-27.1%
1-Year
Split-adjusted
VERA+67.2%IRON+40.7%TARS+62.9%ELVN+141.2%NRIX+88.8%TRVI+201.7%
Year-to-Date (YTD)
VERA-20.8%IRON-3.0%TARS-18.1%ELVN+224.7%NRIX+26.7%TRVI+43.4%

Key Metric Comparison

P/E

Lower is better
VERA—TLX—MSB—CSL30.02Median 17.81

ROE

Higher is better
VERA-71.3%TLX-1.8%MSB-11.3%CSL7.7%Median -47.5%

Net Margin

Higher is better
VERA—TLX-0.9%MSB-115.3%CSL9.2%Median -125.7%

Revenue Growth

Higher is better
VERA—TLX56.3%MSB410.4%CSL4.8%Median 5.1%

P/E

Lower is better

ROE

Higher is better
VERA-71.3%IRON-35.8%TARS-14.0%ELVN-26.6%NRIX-61.4%TRVI-33.6%Median -47.5%

Net Margin

Higher is better
VERA—IRON2,016.9%TARS-9.0%ELVN—NRIX-411.4%TRVI—Median -125.7%

Revenue Growth

Higher is better
VERA—IRON—TARS129.0%ELVN-100.0%NRIX27.2%TRVI-100.0%Median 5.1%

All Metrics

Valuation
MetricVERATLXMSBCSLInd. Median
P/E———30.0217.81
P/B5.746.56—2.24●3.49
EV/EBITDA—123.31—10.37●14.92
P/S—3.3431.912.67●10.89
Financial Health
MetricVERATLXMSBCSLInd. Median
Current Ratio13.64●1.43—2.575.90
Debt/Equity15.0%●112.3%—67.4%10.9%
NetDebt/EBITDA1.46●13.13—2.221.15
Profitability
MetricVERATLXMSBCSLInd. Median
Net Margin—-0.9%-115.3%9.2%●-125.7%
ROE-71.3%-1.8%-11.3%7.7%●-47.5%
ROA-59.9%-0.7%-8.6%3.8%●-35.8%
EBITDA Margin—3.0%-76.6%32.8%●-105.8%
Growth + Dividend
MetricVERATLXMSBCSLInd. Median
Rev. Growth—56.3%410.4%●4.8%5.1%
NI Growth———-39.4%12.1%
Div. Yield——0.0%2.5%●0.2%
Payout——0.0%103.1%0.0%
Valuation
MetricVERAIRONTARSELVNNRIXTRVIInd. Median
P/E——————17.81
P/B5.744.31●8.256.935.5015.183.49
EV/EBITDA——————14.92
P/S—-247.45●5.38—36.86—10.89
Financial Health
MetricVERAIRONTARSELVNNRIXTRVIInd. Median
Current Ratio13.6424.003.7440.32●6.0124.755.90
Debt/Equity15.0%4.5%25.4%0.1%●12.2%0.4%10.9%
NetDebt/EBITDA1.46●2.937.474.591.763.761.15
Profitability
MetricVERAIRONTARSELVNNRIXTRVIInd. Median
Net Margin—2,016.9%●-9.0%—-411.4%—-125.7%
ROE-71.3%-35.8%-14.0%●-26.6%-61.4%-33.6%-47.5%
ROA-59.9%-33.1%-8.9%●-25.7%-47.2%-31.8%-35.8%
EBITDA Margin—1,988.9%●-7.5%—-382.1%—-105.8%
Growth + Dividend
MetricVERAIRONTARSELVNNRIXTRVIInd. Median
Rev. Growth——129.0%●-100.0%27.2%-100.0%5.1%
NI Growth——————12.1%
Div. Yield——————0.2%
Payout——————0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on VERA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.